Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.69 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.64 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.64 |
| ▸ | ALPI | P09923 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | XIAP | P98170 | 1/20 | 0.55 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | GGT1 | P19440 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218877 | 0.86 | MMP2 (0.73) | MMP2ALPIPKMPTGS1XIAP | |
| SCHEMBL218878 | 0.86 | MMP2 (0.73) | MMP2ALPIPKMPTGS1XIAP | |
| SCHEMBL2876751 | 0.86 | MMP2 (0.73) | MMP2ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL23051768 | 0.84 | MMP2 (0.71) | MMP2ALPIPKMPTGS1XIAP | |
| SCHEMBL20717803 | 0.84 | MMP2 (0.71) | MMP2ALPIPKMPTGS1XIAP | |
| SCHEMBL20717933 | 0.84 | MMP2 (0.71) | MMP2ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL23051769 | 0.84 | MMP2 (0.71) | MMP2ALPIPKMPTGS1XIAP | |
| SCHEMBL27791789 | 0.83 | MMP2 (0.65) | MMP2EPHX1GGT1 | |
| SCHEMBL19989734 | 0.83 | MMP2 (0.65) | MMP2EPHX1GGT1 | |
| SCHEMBL6692780 | 0.83 | MTNR1A (0.58) | MMP2MTNR1AMTNR1BALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183443-B2 | Process for the preparation of enantiomerically enriched compounds | DSM IP ASSETS B.V. (NL) | 2007-02-27 | — | — | US | disclosed |
| US-20050215822-A1 | Process for the preparation of enantiomerically enriched compounds | DSM IP ASSETS B.V. (NL) | 2005-09-29 | — | — | US | disclosed |
| EP-1492760-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED COMPOUNDS | DSM IP Assets B.V. (NL) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003087033-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED COMPOUNDS | DSM IP ASSETS B.V. (NL) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215822-A1 | Process for the preparation of enantiomerically enriched compounds | ADH1C, ADH1A, ADH5 | MMP2 966/4885MTNR1A 3334/4885MTNR1B 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.